SCHEMBL5607879

SCHEMBL5607879

N[C@@H](Cc1ccc(CNS(=O)(=O)c2ccc(Cl)cc2)cc1)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.54
MAPK1 P28482 1/20 0.54
HSD17B10 Q99714 1/20 0.54
CYP19A1 P11511 1/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
TP53 P04637 1/20 0.52
POLB P06746 1/20 0.52
NAMPT P43490 2/20 0.50
TUBB P07437 1/20 0.49
ADAMTS5 Q9UNA0 1/20 0.49
MMP2 P08253 1/20 0.49
TBXA2R P21731 1/20 0.49
PRMT1 Q99873 1/20 0.49
CA2 P00918 2/20 0.49
SLC1A3 P43003 1/20 0.49
SLC1A2 P43004 1/20 0.49
SLC1A1 P43005 1/20 0.49
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27755098 1.00 ALDH1A1 (0.54) ALDH1A1MAPK1HSD17B10CYP19A1MEN1
SCHEMBL27754713 0.88 ITGB1 (0.60) ALDH1A1HSD17B10POLBTUBBPRMT1
SCHEMBL5607710 0.88 ITGB1 (0.60) ALDH1A1HSD17B10POLBTUBBPRMT1
SCHEMBL27734537 0.88 CA9 (0.50) CYP19A1PRMT1CA2CA12CA1
SCHEMBL27734539 0.88 CA9 (0.50) CYP19A1PRMT1CA2CA12CA1
SCHEMBL5607840 0.88 KEAP1 (0.61) ALDH1A1NAMPTPRMT1CA2CA12
SCHEMBL27754918 0.88 KEAP1 (0.61) ALDH1A1NAMPTPRMT1CA2CA12
SCHEMBL5608193 0.87 LMNA (0.62) ALDH1A1CYP19A1MEN1KMT2ATP53
SCHEMBL5078452 0.86 LMNA (0.52) MEN1KMT2APOLBPRMT1CA2
SCHEMBL27734717 0.86 LMNA (0.52) MEN1KMT2APOLBPRMT1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101400699-A Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions BRISTOL MYERS SQUIBB CO (US) 2009-04-01 CN claimed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US claimed
CN-101400699-A Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions BRISTOL MYERS SQUIBB CO (US) 2009-04-01 CN disclosed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US disclosed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US disclosed
WO-2007082264-A2 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS GLP1R, GIPR, IAPP ALDH1A1 4570/4885MAPK1 2059/4885HSD17B10 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.